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Cryptococcal meningitis (CM) is now the most common cause 
of adult meningitis in southern Africa1,2 and is a major burden 
on local health care services.3 Treatment remains unsatisfactory, 
with acute mortality in Africa ranging from 30% to 50%, even 
with optimal therapy.4,5 Consequently, CM is a major cause of 
mortality in African HIV-infected patients, accounting for 13 - 
44% of all deaths.6-8 Estimates from the Centers for Disease 
Control and Prevention (CDC) show that CM is responsible for 
504 000 deaths in sub-Saharan Africa annually.9
A sizeable proportion of the cryptococcal disease burden is 
thought to be due to symptomatic relapse of previously treated 
infection. Recent work has highlighted the contribution made 
by immune reconstitution syndrome (IRIS) and fluconazole 
resistance to relapse in South African patients taking secondary 
fluconazole prophylaxis.10-12
Without secondary prophylaxis, at least 50 - 60% of patients 
will have disease relapse.13-15 Properly used secondary 
fluconazole prophylaxis is highly effective, increasing 
recurrence-free survival by more than 13 times at 6 months.16,17 
Fluconazole has been freely available in South Africa since 2001 
via Pfizer’s donation programme, and current South African 
guidelines for the treatment of HIV-associated CM recommend 
fluconazole consolidation treatment for all patients, following 
initial amphotericin B therapy, then secondary fluconazole 
prophylaxis either lifelong or until the CD4 count is >200 for 6 
months on ART.18 However, evidence suggests that the use of 
secondary fluconazole prophylaxis in South Africa is poor, with 
only 31.5% of initial prescriptions re-filled at 2 months, and 
only 6% of patients returning for fluconazole at 1 year.19
To examine the contribution of inadequate fluconazole 
prophylaxis to symptomatic relapses of cryptococcal disease 
we carried out a prospective observational study at GF Jooste 
Hospital, a public sector adult referral hospital in Cape 
Town serving a population of 1.3 million (including a large 
part of Khayelitsha township, population 400 000, with HIV 
antenatal seroprevalence of 32.7% in 2006).20 Cryptococcus is 
the commonest cause of meningitis at the hospital, accounting 
for 63% of microbiologically confirmed cases,21 and the disease 
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Objectives. Cryptococcal meningitis is the most common 
cause of adult meningitis in southern Africa. Much of this 
disease burden is thought to be due to symptomatic relapse 
of previously treated infection. We studied the contribution 
of inadequate secondary fluconazole prophylaxis to 
symptomatic relapses of cryptococcal meningitis. 
Design. A prospective observational study of patients 
presenting with laboratory-confirmed symptomatic relapse 
of HIV-associated cryptococcal meningitis between January 
2007 and December 2008 at GF Jooste Hospital, a public sector 
adult referral hospital in Cape Town.
Outcome measures. Relapse episodes were categorised into: 
(i) patients not taking fluconazole prophylaxis; (ii) immune 
reconstitution inflammatory syndrome (IRIS); and (iii) 
relapses occurring prior to ART in patients taking fluconazole. 
In-hospital mortality was recorded.
Results. There were 69 relapse episodes, accounting for 
23% of all cases of cryptococcal meningitis; 43% (N=30) of 
relapse episodes were in patients not receiving fluconazole 
prophylaxis, 45% (N=31) were due to IRIS, and 12% (N=8) 
were in patients pre-ART taking fluconazole. Patients 
developing relapse due to inadequate secondary prophylaxis 
had severe disease and high in-hospital mortality (33%). Of 
the 30 patients not taking fluconazole, 47% (N=14) had not 
been prescribed secondary prophylaxis by their health care 
providers. We documented no relapses due to fluconazole 
resistance in these patients who received amphotericin B as 
initial therapy.
Conclusions. A large number of relapses of cryptococcal 
meningitis are due to failed prescription, dispensing 
and referral for or adherence to secondary fluconazole 
prophylaxis. Interventions to improve the use of secondary 
fluconazole prophylaxis are essential.
S Afr Med J 2010; 100: 378-382.
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burden is high, with over 100 India ink-positive cases per 
year.22
Methods
Participants
The study was approved by the Research Ethics Committee 
of the University of Cape Town. Between January 2007 and 
December 2008, all patients presenting to GF Jooste Hospital 
with a laboratory-confirmed diagnosis of cryptococcal 
meningitis were prospectively identified. Cases of symptomatic 
relapse were defined as occurring in patients with the 
following characteristics: (i) a previous laboratory-confirmed 
case of CM; (ii) recurrence of typical CM symptoms; (iii) CSF 
India ink, antigen test (CRAG) and/or culture positive for 
Cryptococcus neoformans at this presentation; and (iv) no 
alternative diagnosis.
A patient could be classified as having more than one 
relapse episode, provided that there had been a resolution 
of symptoms and an interval of at least 1 month between 
episodes. During the study period, the standard treatment 
of CM at the hospital consisted of 2 weeks of amphotericin 
B at a dose of 1 mg/kg, followed by fluconazole 400 mg 
daily as consolidation treatment for 8 weeks, then long-term 
secondary prophylaxis with fluconazole 200 mg daily, as per 
current guidelines.18 As part of ongoing clinical studies, 8 of 
our patients had also received additional induction treatment 
during their initial episode (2 received flucytosine, 4 received 
IFNγ and flucytosine, and 2 received fluconazole).
Procedures
Details of previous episodes of CM, current medications 
including antiretroviral therapy (ART) and antifungal 
medications, and self-reported adherence to medications 
were recorded. Reasons for patients not taking fluconazole 
secondary prophylaxis were ascertained by reviewing 
discharge scripts from the initial episode and by patient 
interviews, and categorised into patient non-adherence, 
or failure on the part of health care providers to provide 
the appropriate medication. In patients taking fluconazole 
prophylaxis, episodes were categorised into either IRIS or 
non-IRIS relapses, with IRIS defined as (i) microbiologically 
confirmed first episode of CM, (ii) resolution of CM symptoms 
before starting ART, (iii) self-reported adherence to fluconazole 
and ART, (iv) recurrence of CM symptoms after initiation of 
ART, and (v) no alternative diagnosis, including fluconazole 
resistance, found on laboratory testing and clinical review. All 
patients had a full clinical work-up including lumbar puncture, 
cell counts, protein and glucose quantification, bacterial 
cultures and TB cultures where appropriate, and fluconazole 
mean inhibitory concentrations (MICs) when fluconazole 
resistance was queried. CM-IRIS cases were further categorised 
as either CSF culture-negative or -positive.
During the last 12 months of the study, patients were also 
interviewed by a research nurse to determine their levels of 
knowledge about secondary fluconazole prophylaxis, and 
what education about the importance and correct usage 
of such prophylaxis they were given on discharge from 
hospital. Additional demographic, clinical and laboratory 
data, including HIV status, CD4 counts, CSF findings and 
fluconazole mean inhibitory concentrations (MICs), where 
available, were obtained from patient hospital notes and 
computerised laboratory records. In-hospital mortality was 
recorded for all patients. Fluconazole MICs were determined 
using Etests (AB Biodisk). Plates were incubated at 35°C for 
48 hours, and MICs were the lowest concentration at which 
the elliptical inhibition zone intercepted the scale on the strip. 
Etests have been shown to yield results in good agreement 
with the broth microdilution method.23 A definitive breakpoint 
MIC has yet to be established, and results were therefore 
interpreted on the best available evidence using the following 
criteria: susceptible – MIC ≤8 mg/ml; dose-dependent 
susceptibility – MIC 16 - 32 mg/ml; and resistant – MIC ≥64 
mg/ml.10,24-26
Analysis
Data were analysed using Stata version 10 (StataCorp). 
Continuous variables were described as medians with 
interquartile ranges, and compared using the median test. 
Categorical data were described using proportions and 
compared using Pearson’s χ2 test or Fisher’s exact test. 
Statistical significance was defined as p<0.05. Odds ratios 
for mortality with 95% CIs were calculated using logistic 
regression analysis.
Results
Patients
There were 300 episodes of laboratory-confirmed CM; 69 were 
episodes of symptomatic relapse, occurring in 57 patients (6 
patients had 2 episodes, 1 had 3, and 1 had 5), accounting for 
23% of all laboratory-confirmed cases; 43% (N=30) of relapse 
episodes were in patients not taking fluconazole prophylaxis; 
45% (N=31) were due to IRIS, and the remaining 12% (N=8) 
were relapses in patients taking fluconazole prophylaxis, but 
prior to starting ART (Fig. 1). Education of patients about 
the need for ongoing fluconazole prophylaxis was poor, 
with 38% (9) of 24 patients questioned (12 IRIS cases, 11 not 
taking fluconazole and 1 relapse on fluconazole prior to 
ART) reporting having received no information about the 
requirement for fluconazole secondary prophylaxis. There was 
a correlation between education and adherence to fluconazole. 
Of the 9 who received no education, 7 were non-adherent 
(78%), versus 4 of the 15 (27%) who were educated (p=0.015).
Patient demographic, clinical and laboratory features of 
the relapse episodes are shown in Table I. Overall in-hospital 
mortality was 23%. Factors significantly associated with in-
hospital mortality by univariate analysis were abnormal mental 
status (odds ratio (OR) 7.2, 95% CI 2.1 - 25.0) and high fungal 
burden, evidenced by India ink-positivity (OR 5.0, 95% CI 1.02 
- 24.1).
Inadequate secondary fluconazole prophylaxis
Patients developing symptomatic relapse of CM due to 
inadequate fluconazole prophylaxis had severe disease, with a 
high proportion of abnormal mental status (30%), high fungal 
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burdens (70% India ink-positive) and high in-hospital mortality 
(33%). Patients not taking fluconazole were 2.5 times more 
likely to die in hospital than those on appropriate fluconazole 
prophylaxis (OR, 95% CI 0.8 - 8.0, p=0.11, univariate analysis).
Of the 30 patients not taking fluconazole, 16 (53%) had been 
prescribed fluconazole but were non-adherent to therapy. The 
remaining 14 (47%) had either not been prescribed secondary 
prophylaxis on discharge from hospital after their initial 
episode of CM, or had not been appropriately referred to 
primary care, or the prescription had not been continued by 
their primary care providers.
IRIS
Patients developing symptomatic relapse of CM due to IRIS 
had milder disease, with a lower proportion of abnormal 
mental status (19%) and lower fungal burdens (55% India 
ink-positive) than the other relapse cases, and low in-hospital 
mortality (13%), although these differences did not reach 
statistical significance. IRIS episodes occurred a median of 61 
days (IQR 31 - 146) after commencing ART. CSF cryptococcal 
cultures were positive in 12 (39%) of the IRIS episodes. 
Fluconazole MICs were performed on 10 of these samples. 
None of the samples had an MIC ≥64 µg/ml, suggesting 
fluconazole resistance. One had an MIC of 32 µg/ml, indicating 
dose-dependent susceptibility, raising the possibility that 
decreased fluconazole susceptibility was a factor in this case, 
while the remaining 9 all had MICs ≤8 µg/ml, indicating 
susceptibility to fluconazole. Although neither a documented 
immunological or virological response to ART, nor a decrease 
in fungal burden despite worsening symptoms were required 
for a diagnosis of IRIS, these were recorded in all but 2 
patients. In each of the 19 of 31 IRIS cases where CD4 and viral 
load data were available, all showed a marked decrease in viral 
load, and rising CD4 counts. In terms of decreasing fungal 
burden, 19 of 31 cases were culture-negative, having been 
culture-positive during the initial episode. A further 4 of the 
culture-positive cases had a low fungal burden as evidenced 
by being India ink-negative at the relapse presentation, 2 more 
had very scanty growth at the relapse presentation, and 2 had a 
documented decrease in cryptococcal latex antigen test (CLAT) 
titre. Of the 2 patients who did not have either a documented 
immunological and viral response, or a documented decrease 
in fungal burden despite worsening symptoms, a diagnosis 
of IRIS was clinically made, after ruling out other potential 
diagnoses, including possible fluconazole resistance (both had 
fluconazole MICs indicating susceptibility, and were reportedly 
adherent to their medication).
Relapses prior to ART
Eight patients developed symptomatic relapse episodes while 
reporting adherence to appropriate secondary fluconazole 
prophylaxis, but before commencing ART. Of these, 4 were 
early relapses (within 1 month of discharge), and probably 
represent failure to respond to initial treatment rather than 
true relapse. The remaining 4 cases occurred at 50, 70, 104 
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Fig. 1. Causes of symptomatic relapse of cryptococcal meningitis, divided 
into immune reconstitution inflammatory syndrome (IRIS) in patients 
taking ART, absence of fluconazole secondary prophylaxis (subdivided into 
patient non-adherence and not given – either not prescribed, not dispensed, 
or not continued at primary care level), and relapses in patients taking 
fluconazole prior to starting ART.
Table I. Demographics, clinical features and outcomes of 69 episodes of symptomatic relapse of cryptococcal meningitis 
   IRIS (N=31)      No fluconazole (N=30)           Pre-ART, on fluconazole (N=8)              p-value*
Age (years)  33 (29 - 42)†      35 (28 - 42)            33 (26 - 39)                0.63
Sex (% male)  52%       50%             50%                0.99
CD4 count (cells/µl)‡ 77 (15 - 130)      46 (20 - 154)            60 (39 - 109)                0.84
Time from initial episode to  87 (56 - 146)      103 (67 - 156)            48 (23 - 96)                0.28
relapse (days)
On TB treatment  37% (11)       46% (12)            25% (2)                0.53
Abnormal mental   19% (6)       30% (9)            25% (2)                0.63
status (%)§
CSF lymphocytes (x106/l) 7 (4 - 65)       8 (1 - 58)            6 (1 - 56)                0.99
CSF protein (g/dl)  1.08 (0.8 - 1.6)      0.97 (0.5 - 2.0)            0.4 (0.3 - 0.8)                0.07
CSF glucose (mmol/l) 2.0 (1.5 - 2.7)      2.0 (1.2 - 2.7)            2.6 (1.5 - 3.1)                0.28
India ink- positive (%) 55% (17)       70% (21)            88% (7)                0.17
In-hospital mortality 13% (4)       33% (10)            25% (2)                0.17
* p-values were calculated using Pearson’s χ2-test or the median test.
† Continuous variables are expressed as median (inter-quartile range).
‡ CD4 cell count at time of relapse or most recent count within 6 months prior to relapse.
§ Abnormal mental status was defined as any reduction in level of consciousness (confusion or Glasgow coma score < 15) or a history of seizures.
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and 196 days after the initial episode. Fluconazole MICs were 
performed in 2 of the 4 cases, and were both ≤8µg/ml. In 3 
of these 8 cases, treatment of the initial episode of CM was 
inadequate (1 patient received fluconazole monotherapy, 2 had 
less than 2 weeks of amphotericin B). Two of the 3 patients 
who received inadequate initial therapy relapsed early (at 21 
and 26 days after initial diagnosis), supporting the suggestion 
that these early relapses represented failure of initial treatment. 
The third patient relapsed at 50 days.
Discussion
Symptomatic relapse cases account for a large proportion (23%) 
of all CM cases admitted to our hospital; 43% of these episodes 
occur in patients not taking secondary fluconazole prophylaxis, 
and whose outcomes are poor, with one-third dying in hospital. 
Much of this morbidity, mortality and the associated costs to 
the health service are entirely preventable, as evidence for the 
efficacy of fluconazole consolidation and maintenance therapy 
is strong,16,17,27 treatment guidelines are clear,18 and the drug is 
made freely available to the South African public health care 
sector. That so many patients are presenting with symptomatic 
relapses while not taking fluconazole demonstrates a failure of 
the health care services, and highlights inadequacies in patient 
education, discharge planning and communication between 
secondary and primary providers. In 47% of these cases, 
fluconazole had not been prescribed or dispensed by health 
care providers, or patients had not been properly referred to 
primary care services for continuation of their fluconazole. In 
the remaining cases, patient non-adherence, in part, reflects 
a lack of patient education surrounding the importance of 
secondary prophylaxis – 38% of patients questioned reported 
having received no relevant education. Factors probably 
contributing to the inadequate patient education, and poor 
prescription, dispensing of, and referral for fluconazole in 
our setting, in common with many public sector health care 
facilities in South Africa, are heavy workloads, high turnover 
of junior staff, and language barriers.
Even with appropriate secondary fluconazole prophylaxis, 
not all cases of symptomatic relapse can be prevented; 45% of 
relapses in this study were due to IRIS, and 12% occurred in 
patients prior to ART, despite taking fluconazole. Cryptococcal 
IRIS is well recognised and occurs in 6 - 30% of patients with 
cryptococcal meningitis following commencement of ART.2,29 
IRIS accounted for 10% (31 of 300) of all our CM episodes, 
occurring at a median of 61 days after commencing ART, 
consistent with 3 South African cohorts where the median 
time to onset of IRIS symptoms after starting ART was 1 - 2 
months.10,12,30 Compared with the non-IRIS relapse cases in this 
cohort, the patients presenting with IRIS had less severe clinical 
disease, lower fungal burdens and a lower mortality of 13%.
There were few cases of symptomatic relapse in this 
cohort occurring in patients taking fluconazole and prior to 
commencing ART. Once very early relapses (within 1 month), 
which probably represented ongoing manifestations of the 
initial presentation, were excluded, there were only 4 patients 
in this category. These cases may represent true failures of 
fluconazole prophylaxis, although poor fluconazole adherence 
is a possibility, as we only assessed adherence by self-reporting. 
In the 2 cases without MICs available, fluconazole resistance 
cannot be excluded as a factor.
Of note was that no fluconazole-resistant isolates of C. 
neoformans (MIC ≥64 µg/ml) were seen during the entire 
2-year study period, contrasting markedly with an earlier 
study involving patients from the same hospital.10 Between 
2003 and 2005, after patients not taking fluconazole secondary 
prophylaxis were excluded, 32 relapse episodes in 27 patients 
were reported. Of these, 21 were culture-positive, of whom 14 
had isolates with resistance to fluconazole (MIC ≥64 µg/ml), 
and a further 2 had isolates with dose-dependent susceptibility 
(MIC 16 - 32 µg/ml).10 An explanation for this disparity is the 
switch to amphotericin B as initial treatment at our hospital, in 
early 2005. At the time of the 2003 - 2005 study, the standard 
initial therapy for CM was fluconazole monotherapy 400 mg/
day. Clearance of cryptococci from CSF is very slow with 
fluconazole,4 a fungistatic agent, and the use of fluconazole 
as initial therapy might have promoted drug resistance 
development owing to ongoing high fungal burdens and drug 
exposure over prolonged periods.31 The fungicidal effects 
of amphotericin B, leading to faster clearance of cryptococci 
from the CSF,4 followed by switching to fluconazole once the 
fungal burden had been markedly reduced, appears to have 
minimised the risk of developing later fluconazole resistance.
Our study had several limitations, notably the reliance on 
patient self-reporting of both fluconazole adherence, and 
of education received relating to secondary prophylaxis on 
discharge from hospital after the initial meningitis episode. 
While the number of patients developing relapse prior to 
ART while reporting adherence to fluconazole was small, and 
false reporting of non-adherence is unlikely, non-adherence to 
fluconazole cannot be entirely ruled out as a factor in some of 
the culture-positive IRIS cases.
In conclusion: relapses of previously treated disease 
constitute a significant proportion of the CM disease burden. A 
switch from fluconazole to amphotericin B as initial treatment 
has been associated with virtual elimination of the problem of 
secondary fluconazole resistance at our centre. However, large 
numbers of relapses are due to inadequate use of secondary 
fluconazole prophylaxis, and are entirely preventable. Efforts 
must be made to strengthen both patient and provider 
knowledge about the importance of secondary fluconazole 
prophylaxis in treatment of CM and to improve health system 
performance in this regard.
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